← Leaderboards
Christian Young
Allander Biotechnologies, Inc.
$3,852,072
Attributed
$8,551,834
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2017–25$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,551,834 · 6
By mechanism
R44$5,925,801 · 4
SB1$2,470,033 · 1
R03$156,000 · 1
Top collaborators
- Xiao-Jing Wang9 shared
- Heather Callahan4 shared
Most similar at Allander Biotechnologies, Inc.
Same institution · by research overlap
- Heather Callahan$1,003,690
Others in their field
Other Emerging Leaders on “Funding”
- Leonard Freedman · Leidos Biomedical Research, Inc.$968,195,877
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Lynn Briscoe · Leidos Biomedical Research, Inc.$295,272,057
- Chanza Baytop · Westat, Inc.$271,217,917
- Valerie Koch · University Corporation For Atmospheric Res$251,636,500
Research focus
FundingDrug KineticsHiv-1Topical ApplicationDoseBiotechnologyInvestigational DrugsHealingProteinsPharmacodynamic BiomarkerToxic EffectToxicologyRodentCancer PatientRadiationPreventPeptidesPhase I Clinical TrialsProductionCellsKeratinocyte Growth FactorCanis FamiliarisDesignFormulation
Grant awards (10)
First-in-human clinical trial of proprietary oral gel to treat radiation-induced oral mucositis in cancer patients$1,233,852
R44 · FY2025 · CA · contact PI
Sex-specific immune microenvironment in oral cancer$156,000
R03 · FY2025 · DE · contact PI
IND-enabling toxicology studies to reach IND approval for a proprietary biologic to treat oral mucositis in cancer patients$1,230,285
SB1 · FY2024 · DE · contact PI
IND-enabling toxicology studies to reach IND approval for a proprietary biologic to treat oral mucositis in cancer patients$1,239,748
SB1 · FY2023 · DE · contact PI
Proprietary drug to treat radiodermatitis$522,893
R44 · FY2021 · AR · contact PI
Proprietary drug to treat radiodermatitis$1,157,986
R44 · FY2020 · AR · contact PI
Proprietary biologic treatment to heal skin wounds$715,021
R44 · FY2019 · DE · contact PI
Proprietary biologic treatment to heal skin wounds$796,049
R44 · FY2018 · DE · contact PI
Topical proprietary biologic to treat oral mucositis$702,863
R44 · FY2018 · DE · contact PI
Topical proprietary biologic to treat oral mucositis$797,137
R44 · FY2017 · DE · contact PI